Cytokinetics Inc CYTK:NASDAQ

Last Price$39.76NASDAQ Closing Price as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.97(2.50%)
Bid (Size)$39.55 (1)
Ask (Size)$40.26 (1)
Day Low / High$38.03 - 39.85
Volume821.8 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/20/2022


Cytokinetics Inc ( NASDAQ )

Price: $39.76
Change: +0.97 (2.50%)
Volume: 821.8 K
4:00PM ET 5/20/2022

Mirati Therapeutics Inc ( NASDAQ )

Price: $63.35
Change: +3.74 (6.27%)
Volume: 821.3 K
4:00PM ET 5/20/2022

Ultragenyx Pharmaceutical Inc ( NASDAQ )

Price: $48.55
Change: +1.55 (3.30%)
Volume: 1.2 M
4:00PM ET 5/20/2022

Karuna Therapeutics Inc ( NASDAQ )

Price: $104.53
Change: +0.46 (0.44%)
Volume: 173.1 K
4:00PM ET 5/20/2022

Pacira Biosciences Inc ( NASDAQ )

Price: $63.59
Change: +0.55 (0.87%)
Volume: 351.3 K
4:00PM ET 5/20/2022

Read more news Recent News

Insider Sell: Cytokinetics
5:14PM ET 5/18/2022 MT Newswires

Robert I Blum, Director, President & CEO, on May 16, 2022, sold 10,000 shares in Cytokinetics (CYTK) for $431,065. Following the Form 4 filing with the...

--Mizuho Securities Lifts Cytokinetics' Price Target to $80 From $54, Citing Aficamten Sales Estimates; Buy Rating Kept
4:34AM ET 5/16/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Reports Q1 Revenue $1.1M
4:01PM ET 5/04/2022 MT Newswires


--Oppenheimer Adjusts Cytokinetics Price Target to $57 From $53, Maintains Outperform Rating
12:28PM ET 4/29/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionCytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA. View company web site for more details
Address350 Oyster Point Boulevard
South San Francisco, California 94080
Number of Employees130
Recent SEC Filing05/18/20228-K
President, Chief Executive Officer & DirectorRobert I. Blum
Vice President-Development OperationsEric Terhaerdt
Chief Financial Officer & Senior Vice PresidentChing W. Jaw
Executive Vice President-Research & DevelopmentFady Ibraham Malik

Company Highlights

Price Open$39.23
Previous Close$38.79
52 Week Range$17.72 - 47.90
Market Capitalization$3.4 B
Shares Outstanding85.7 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.20
Beta vs. S&P 500N/A
Revenue$31.5 M
Net Profit Margin-365.84%
Return on Equity-178.55%

Analyst Ratings as of 01/31/2022

Consensus RecommendationConsensus Icon
Powered by Factset